Asparaginase Erwinia Chrysanthemi

CHEMBL1863514 Phase 4 Одобрено Enzyme
Half-Life
Bioavailability
Protein Binding
Molecular Weight
g/mol
LogP
Phase
4

A form of asparaginase derived from the bacterium Erwinia chrysanthemi, used in patients with acute lymphoblastic leukemia who have developed hypersensitivity to other asparaginase preparations. It depletes blood asparagine levels to inhibit leukemia cell growth.

Терапевтические области

Pharmacokinetics (PK)

Pharmacodynamics (PD)

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Часто задаваемые вопросы

A form of asparaginase derived from the bacterium Erwinia chrysanthemi, used in patients with acute lymphoblastic leukemia who have developed hypersensitivity to other asparaginase preparations. It depletes blood asparagine levels to inhibit leukemia cell growth.

Yes, Asparaginase Erwinia Chrysanthemi is an approved drug. It has reached clinical phase 4. It is classified as a Enzyme.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1863514. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

Медицинский отказ от ответственности

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.